Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264749 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA4ACHEBCHE | |
| SCHEMBL31378832 | 0.88 | TDO2 (0.33) | — | |
| SCHEMBL12489908 | 0.77 | PDK2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL2794267 | 0.74 | MAP3K12 (0.34) | — | |
| SCHEMBL31378727 | 0.72 | — | — | |
| SCHEMBL3371065 | 0.71 | GRM4 (0.32) | — | |
| SCHEMBL3351059 | 0.71 | OPRL1 (0.40) | — | |
| SCHEMBL22165236 | 0.71 | ABL1 (0.34) | — | |
| SCHEMBL16110827 | 0.71 | GAA (0.34) | — | |
| SCHEMBL14910572 | 0.71 | NOS3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | CHRNB2 4352/4885CHRNA4 4195/4885ACHE 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.